Vivo Bio Tech Share Price Today | Stock Price & Vivo Bio Tech Share Screener
As of October 5, 2026, the live Vivo Bio Tech share price (NSE: VIVOBIOT) is ₹15.14 on NSE and ₹14.98 on BSE, down 11.62% from the previous close, with shares trading between ₹14.60 and ₹17.83 in today's trading session, and a 52-week range of ₹15.14–₹19.68. Check Vivo Bio Tech yearly highs lows for the annual price range and momentum. Use the Vivo Bio Tech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vivo Bio Tech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹14 and net income of ₹-5, with EBITDA of ₹5, an operating margin of 31.0% and a profit margin of -35.7%.
Vivo Bio Tech Share Price Chart
Track the current stock price of Vivo Bio Tech with an interactive chart. Analyse VIVOBIOT share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vivo Bio Tech stock quote in one place.
The quote of ₹15.14 sits between the 52-week low of ₹15.14 and the 52-week high of ₹19.68, and the latest session moved -11.62% from the previous close.
Vivo Bio Tech Company Profile - Fundamental Screener
Screen Vivo Bio Tech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VIVOBIOT shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Biotechnology industry, and it trades under ISIN INE380K01017.
Company Details
Classification
Identifiers and Leadership
Vivo Bio Tech Balance Sheet Screener
Screen VIVOBIOT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹178, up from ₹143 in 2025.
Latest statistics put total assets at ₹178 and shareholder funds at ₹93, with a leverage ratio of 0.71.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 178 | 143 | 137 | 123 | 123 | 80 | 64 | 55 | 60 | 51 |
| Current Assets | 28 | 42 | 47 | 32 | 26 | 27 | 27 | 25 | 28 | 20 |
| Fixed Assets | 123 | 88 | 80 | 89 | 95 | 52 | 35 | 30 | 28 | 29 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 55 | 38 | 45 | 46 | 52 | 15 | 10 | 9 | 15 | 22 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 93 | 78 | 54 | 52 | 47 | 43 | 33 | 27 | 19 | 13 |
| Share Capital | 22 | 17 | 15 | 15 | 14 | 13 | 13 | 12 | 10 | 9 |
| Reserves & Surplus | 69 | 54 | 40 | 37 | 32 | 28 | 20 | 15 | 7 | 3 |
Vivo Bio Tech Income Statement Screener - Profit & Revenue Analysis
Screen Vivo Bio Tech income statement and profit fundamentals. Analyze VIVOBIOT quarterly results. Vivo Bio Tech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹14 and net profit was ₹-5, equal to earnings per unit of ₹-2.52, at an operating margin of 31%.
In that period expenses were ₹10, interest cost ₹2 and tax ₹5. The next period listed, 2026-Jun, shows revenue of ₹14 and net profit of ₹0.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 14 | 14 | 12 | 13 | 13 | 14 | 12 | 10 | 17 | 12 | 15 | 12 | 9 | 13 | 15 |
| Expenses | 10 | 9 | 7 | 7 | 8 | 8 | 6 | 6 | 6 | 7 | 8 | 7 | 4 | 7 | 14 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 5 | 5 | 5 | 6 | 6 | 6 | 5 | 4 | 10 | 6 | 7 | 5 | 5 | 6 | 2 |
| Operating Profit % | 31.00% | 35.00% | 41.00% | 44.00% | 41.00% | 41.00% | 46.00% | 43.00% | 47.00% | 45.00% | 48.00% | 39.00% | 52.00% | 50.00% | 11.00% |
| Depreciation | 3 | 4 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 6 | 2 | 3 | 0 | 1 | 2 | -2 |
| Tax | 5 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | -1 |
| Net Profit | -5 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 5 | 1 | 2 | 0 | 0 | 1 | -1 |
| EPS | -2.52 | 0.08 | 0.69 | 0.74 | 0.45 | 0.56 | 0.50 | 0.11 | 3.51 | 0.55 | 1.38 | 0.10 | 0.22 | 0.89 | -0.49 |
Vivo Bio Tech Cash Flow Screener - Liquidity Fundamentals
Screen VIVOBIOT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹35.
Over the same period, investing activities used ₹59 and financing activities provided ₹25.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 35 | 12 | 16 | 15 | 17 | 14 | 9 | -1 | 11 | -6 |
| Investing Activities | -59 | -16 | -8 | -4 | -51 | -23 | -10 | -4 | -5 | -12 |
Financing and Net Cash | ||||||||||
| Financing Activities | 25 | 4 | -8 | -11 | 35 | 9 | 2 | 1 | -3 | 7 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 1 | 0 | 1 | -4 | 3 | -11 |
Vivo Bio Tech Shareholding Pattern Screener
See Vivo Bio Tech shareholding pattern with promoter, FII, and DII holdings. Check Vivo Bio Tech promoter holding and ownership changes for VIVOBIOT on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 35.43%, foreign institutions 0.00%, domestic institutions 0.00% and the public 32.37%, spread across 21,427 shareholders.
The shareholder count was 21,427 in 2026-Mar, compared with 21,224 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Apr | 2025-May | 2025-Jun | 2025-Aug | 2025-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 35.43% | 30.62% | 40.85% | 43.36% | 42.29% | 39.06% | 36.43% | 35.16% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.37% | 32.52% | 34.74% | 33.27% | 35.48% | 34.39% | 33.48% | 32.30% |
| Other Holding | 32.20% | 36.87% | 24.41% | 23.37% | 22.23% | 26.55% | 30.09% | 32.53% |
| Shareholder Count | 21,427 | 21,224 | 21,169 | 21,935 | 21,909 | 21,896 | 21,890 | 21,659 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vivo Bio Tech. Vivo Bio Tech dividend yield can be compared with peers and other stocks in the market.
Vivo Bio Tech Stock Index Membership - Nifty & Sensex
See which indices include Vivo Bio Tech stock. Check VIVOBIOT index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Vivo Bio Tech Market Events Screener - Corporate Actions
Get Vivo Bio Tech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vivo Bio Tech stock events that may affect VIVOBIOT share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated July 13, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -13.78% |
| 2026-07-13 | 2026-07-13 | Quarterly Result Announcement | NA | 0.86% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 1.77% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 0.46% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.46% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.59% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 13.72% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 3.47% |
| 2025-02-07 | 2025-02-07 | Extraordinary General Meeting | NA | -8.43% |
| 2025-01-09 | 2025-01-09 | Quarterly Result Announcement | NA | 27.98% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.94% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 0.96% |
Vivo Bio Tech Competitors Screener - Peer Stocks Comparison
Screen VIVOBIOT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 6 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 48,224 | 83.88 | 2,280 | 18.12% | 592 | 39.50 |
| Advanced Enzyme Tech | 3,048 | 18.30 | 781 | 16.51% | 174 | 28.77 |
| CCME Global | 188 | -229.95 | 4 | % | 0 | 43.71 |
| Vivo Bio Tech | 38 | -13.17 | 54 | 4.47% | -2 | 44.21 |
| Shree Ganesh Bio-Tech | 19 | -47.00 | 6 | -73.77% | 0 | 40.94 |
| Genomic Valley Biotech | 9 | 434.14 | 0 | -66.25% | 0 | 46.78 |
Vivo Bio Tech Company Announcements - News & Reports Screener
Screen VIVOBIOT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 2, 2026 and October 2, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-10 | Re-Lodgement Of Transfer Requests Of Physical Shares. | - |
| 2026-09-09 | Web Link Intimation | - |
| 2026-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-08 | Reg. 34 (1) Annual Report. | - |
| 2026-09-08 | 39Th Annual General Meeting Notice. | - |
| 2026-08-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-24 | Expiry Of Warrants | - |
| 2026-08-24 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-24 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-24 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-22 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-22 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-08-21 | Expiry Of Warrants | - |
| 2026-08-20 | Expiry Of Warrants | - |
| 2026-07-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-14 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹15.14, within a 52-week range of ₹15.14 to ₹19.68. The P/E ratio is -13.17 and the P/B ratio is 0.41, with earnings per unit of ₹-0.82. Market capitalisation stands at ₹38.01 Cr. The company operates in the Healthcare sector, in the Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.